Autoimmune adverse event following COVID-19 vaccination in Seoul, South Korea
- 주제(키워드) autoimmune adverse events , complications , COVID-19 , vaccination , vitiligo
- 후원정보 Elsevier Inc.
- 등재 SCIE, SCOPUS
- OA유형 Hybrid
- 발행년도 2024
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000240267
- 본문언어 영어
- Published As https://doi.org/10.1016/j.jaci.2024.01.025
- PubMed https://pubmed.ncbi.nlm.nih.gov/38520423
초록/요약
Background: There is growing evidence that the coronavirus disease 2019 (COVID-19) vaccination can affect the regulation of the immune system, leading to the development of autoimmune diseases. However, the autoimmune adverse events (AEs) after COVID-19 vaccination remain largely unclear. Objective: We sought to investigate the autoimmune AEs after COVID-19 vaccination from a population-based cohort in South Korea. Methods: A total of 4,203,887 participants, representing 50% of the population residing in Seoul, were recruited from the National Health Insurance Service database and then divided into 2 groups on the basis of COVID-19 vaccination. The cumulative incidence, hazard ratios (HRs), and 95% CIs of autoimmune AEs were assessed following COVID-19 vaccination. Results: The incidence of vitiligo has been observed to be significantly higher in the vaccination group compared with the no vaccination group. The cumulative incidence of vitiligo began to show a significant difference starting 2 weeks after vaccination, and it reached 2.2% in the vaccination group and 0.6% in the no vaccination group by 3 months after COVID-19 vaccination. Vitiligo (HR, 2.714; 95% CI, 1.777-4.146) was an increased risk among autoimmune AEs. Furthermore, the risk of vitiligo was the highest for heterologous vaccination (HR, 3.890; 95% CI, 2.303-6.573) compared with using cDNA vaccine (HR, 2.861; 95% CI, 1.838-4.453) or mRNA vaccine (HR, 2.475; 95% CI, 1.607-3.813). Conclusions: Vitiligo as an autoimmune AE was noted to be substantially higher in the COVID-19–vaccinated group compared with the controls. Therefore, the occurrence of vitiligo could be considered as one of the significant AEs post–COVID-19 vaccination. © 2024 The Authors
more